Radiopharm Theranostics Limited American Depositary Shares reports a Return on Equity (ROE) of -51.17%.

What is RADX's dividend yield?

Radiopharm Theranostics Limited American Depositary Shares offers a dividend yield of 0.00%.

What is RADX's Quality Score?

Our AI rates RADX's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy RADX?

Our AI Timing Score for RADX is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does RADX belong to?

Radiopharm Theranostics Limited American Depositary Shares is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Radiopharm Theranostics Limited American (RADX) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-05 | FS: 2025-12-31)

RADX AI Analysis Summary

Our AI summary for RADX: Radiopharm Theranostics Limited American Depositary Shares (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -51.17%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

RADX

Radiopharm Theranostics Limited American Depositary Shares

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 2.78

-0.14 (-4.79%) Day Change

Watchlist Portfolio Compare Chart

0.80

D/E

-51.2%

ROE

-29.1%

ROA

0.00%

Div Yield

RADIOPHARM THERANOSTICS LIMITED AMERICAN DEPOSITARY SHARES
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 2.78 Price -0.14 (-4.79%) Day Change	NEWS SCORE: 87

RADX, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

44%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	87
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	2.78
PBV / Sector	0.46 / 44,105.10 GREAT
Earning Per Share	-3.20

PE / Sector	N/A / 19.37
PEG or PE/Growth / Sector	N/A / 1.06
Average 1M Daily Value	0.49 M GREAT
Average 1W Daily Value	0.24 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

47%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-1,946.20 / 97.23
NPM Average (%) / Sector	-74,883.05 / -1,697.84
NPM Change Average (%) / Sector	-17.55 / 5,097.59
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-29.06 / 185,260.64
ROA Average (%) / Sector	-44.51 / 36,684.64
ROA Change Average (%) / Sector	0.80 / 422,221.42
ROE (%) / Sector	-51.17 / 243,761.81
ROE Average (%) / Sector	-86.69 / 48,758.38
ROE Change Average (%) / Sector	22.62 / 424,967.86 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.42

Registration Details

Analyze Date	2026-08-06 08:00:34
Symbol	RADX
Name	RADIOPHARM THERANOSTICS LIMITED AMERICAN DEPOSITARY SHARES
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	7.88 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	23.02 / 9,702.21

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 62 Lygon Street, Carlton, VIC, Australia, 3053

Phone: 61 3 9824 5254

Website: https://www.radiopharmtheranostics.com

Sector: Healthcare >> Biotechnology

Description: Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops several products, including RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic. Additionally, it is developing RAD301 and RAD302, which are Avß6-Integrin pancreatic diagnostic and therapeutic products; RAD401, a PSA-mAb prostate cancer diagnostic; RAD402, a PSA-mAb prostate cancer therapeutic; RAD601, a PTPµ glioblastoma diagnostic; and RAD602, a PTPµ glioblastoma therapeutic. The company has a strategic agreement with Lantheus Holdings, Inc. to advance the clinical development of radiopharmaceuticals. The company was incorporated in 2021 and is based in Carlton, Australia.